Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

User experienced hair regrowth using Min, Fin, RU, micro needling, and keto. Others encouraged consistency and shared excitement for future progress.

Topical Dutasteride may halt hair loss and effectively treat androgenic alopecia. Combining low-dose oral Dutasteride with topical application could maximize regrowth and minimize side effects.

A user shared their year-long hair loss treatment using minoxidil, microneedling, and scalp massages, reporting moderate hair growth and stabilization. They suggest starting early with less harmful methods and consider adding finasteride or dutasteride if needed.

A user who underwent exosomes treatment for hair loss and reported their experience, with other users discussing the procedure and offering advice. They discussed options such as finasteride, minoxidil, RU58841 and hair transplants.

The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.

The conversation is about the potential of the RCH-01/Replicel hair loss treatment and its lack of updates since 2013, with the user expressing hope for its success and considering using Minoxidil, finasteride, and dermarolling in the meantime. Other treatments mentioned as promising are Breezula and Tsuji.

The conversation advises against waiting for future hair loss treatments and suggests using proven treatments like Finasteride and Minoxidil. Some users regret not starting treatment earlier, while others discuss the effectiveness and safety of current treatments and the potential of microneedling.

Creatine is unlikely to worsen hair loss for those on finasteride, with no strong scientific evidence linking it to increased hair loss. Many users report no negative effects on hair while using creatine.

A 17-year-old user reports significant hair regrowth using 1mg finasteride daily and 5% minoxidil once daily. Other users discuss the effectiveness and age considerations of finasteride.

A 32-year-old man has been treating his hair loss with daily oral finasteride (1.25g), twice-daily topical minoxidil, weekly ketoconazole 2% shampoo, and weekly microneedling for almost three months, with no side effects from finasteride. He started with a Hamilton Norwood scale rating of 5 and has seen improvement without experiencing pain by using a 0.8mm needle length for microneedling.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

There is no imminent cure for hair loss, but treatments like Minoxidil, Finasteride, and new drugs such as KX-826, GT-20029, and PP405 are being explored. Current solutions focus on slowing hair loss and stimulating growth, with hopes for better options in the future.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

A 19-year-old shared progress on hair regrowth after using minoxidil for a year and starting finasteride. Users discussed the effectiveness and side effects of these treatments, with some expressing concerns about potential side effects and others sharing positive experiences.

Long-term finasteride use typically slows hair loss, with some users experiencing side effects like sexual dysfunction and depression. Many users also use minoxidil and dutasteride for improved results, though individual responses vary.

A 28-year-old male experiencing hair thinning is considering minoxidil and finasteride. Minoxidil helps regrow hair, while finasteride prevents further loss; both are usually lifelong treatments.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Creatine may counteract minoxidil's hair growth effects by closing potassium ATP channels, potentially leading to hair loss in predisposed individuals. Despite anecdotal reports, there is no conclusive evidence linking creatine to hair loss.

Exploring the idea of using facial hair properties for scalp regeneration in male pattern baldness, considering the potential of transferring androgen-resistant characteristics from facial hair to the scalp. Challenges include complexity, scalability, aesthetics, and safety, but the concept encourages innovative thinking beyond current treatments like Minoxidil, Finasteride, and hair transplants.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

Finasteride and dutasteride can prevent hair loss if used early, but they may cause side effects. Many men shave their heads because they are unaware of these treatments or avoid them due to side effects or cost.

The conversation is about using a dermastamp for hair loss treatment and concerns about a potentially scam product, pp405. It suggests sticking with known treatments like finasteride and minoxidil.

Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

A user shared their successful experience with hair regrowth and transitioning from male to female using minoxidil, finasteride, Nutrafol, microneedling, and hormone replacement therapy (HRT). They expressed gratitude for the results and encouraged others to explore treatments that align with their personal goals.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The conversation is about a user's positive hair regrowth results using oral Dutasteride (DUT) and topical Minoxidil (MIN), with occasional derma rolling. The user experienced initial shedding but saw improvement after 8 months, and others discussed the use of Finasteride (FIN) and Tretinoin to enhance results.